Digestive Diseases and Sciences

, Volume 38, Issue 12, pp 2287–2293 | Cite as

Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis

  • I. C. E. Wesdorp
  • W. Dekker
  • H. P. M. Festen
Original Articles
Received:
Revised:
Accepted:

Abstract

Two different doses of famotidine (20 mg twice a day versus 40 mg twice a day) were evaluated in a double-blind, randomized multicenter study in 474 symptomatic patients with erosive ulcerative reflux esophagitis. A total of 238 patients were treated with famotidine 20 mg and 236 patients with 40 mg at breakfast and dinnertime. Relief of symptoms was significant in all patients after six and 12 weeks and not different in both treatment groups. Overall endoscopic healing was significantly better in the famotidine 40 mg twice a day group compared with 20 mg twice a day at week 6 (58% versus 43%;P<0.05) and at week 12 (76% versus 67%;P<0.05). Extending treatment to 24 weeks with 40 mg of famotidine twice a day in those patients not healed after 12 weeks did not result in further symptom relief or in significantly better overall healing. The differences in efficacy of these two doses were more pronounced with increasing severity of esophagitis. Analyzed by grade of esophagitis at entrance, healing was significantly better with famotidine 40 mg twice a day at week 6 for grade II, at week 12 for grades III and IV, and at week 24 for grade IV esophagitis. The results show that in the treatment of erosive/ ulcerative reflux patients famotidine 40 mg twice a day is more effective and achieves faster healing than famotidine 20 mg twice a day.

Key Words

famotidine erosive/ulcerative reflux esophagitis 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Koelz HR: Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. Scand J Gastroenterol 156:25–36, 1989Google Scholar
  2. 2.
    Meuwissen SGM, Klinkenberg-Knol EC: Treatment of reflux esophagitis with H2-receptor antagonists. Scand J Gastroenterol 23:201–213, 1988Google Scholar
  3. 3.
    Colin-Jones DG: Histamine H2-receptor antagonists in gastro-oesophageal reflux. Gut 30:1305–1308, 1989Google Scholar
  4. 4.
    Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G, Fehr HF, Fumagalli I, Gehrig J, Gonvers JJ, Halter F, Hammer B, Kayasseh L, Kobler, E, Miller G, Münst G, Pelloni S, Realini S, Schmid P, Voirol M, Blum A: Healing and relapse rate of reflux oesophagitis during treatment with ranitidine. Gastroenterology 91:1198–1205, 1986Google Scholar
  5. 5.
    Johnson NJ, Boyd EJS, Mills JG, Wood JR: Acute treatment of reflux oesophagitis: A multi-centre trial to compare 150 mg ranitidine bd with 300 mg ranitidine qds. Aliment Pharmacol Ther 3:259–266, 1989Google Scholar
  6. 6.
    Ruth M, Enbom H, Lundell L, Lohnroth H, Sandberg N, Sandmark S: The effect of omeprazole or ranitidine treatment on 24-hour esophageal acidity in patients with reflux esophagitis. Scand J Gastroenterol 23:1141–1146, 1988Google Scholar
  7. 7.
    Schaub N, Meyrick Thomas J, Misiewicz JJ, Lovell D, Trotman IF: Investigation of ranitidine 150 mg bd or 300 mg bd in the treatment of reflux disease. Hepato-Gastroenterol 33:208–213, 1986Google Scholar
  8. 8.
    Quik RFP, Cooper MJ, Gleeson M, Hentschel E, Schuetze K, Kingston RD, Mitchell M: A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis. Aliment Pharmacol Ther 4:201–211, 1990Google Scholar
  9. 9.
    Havelund T, Laursen LS, Skoubo-Kristensen E, Andersen BN, Pedersen SA, Jensen KB, Fenger C, Hanberg-Sorensen F, Lauritsen K: Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J 296:89–92, 1988Google Scholar
  10. 10.
    Dehn TCB, Shepherd HA, Colin-Jones D, Kettlewell MGW, Carroll NJH: Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH-monitoring. Gut 31:509–513, 1990Google Scholar
  11. 11.
    Bardhan KD, Morris P, Thompson M, Dhande DS, Hinchliffe RFC, Jones RB, Daly MJ, Caroll NJH: Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine. Gut 31:745–749, 1990Google Scholar
  12. 12.
    Bate CM, Keeling PWN, O'Morain C, Wilkinson SP, Foster DN, Mountford RA, Temperley JM, Harvey RF, Thompson DG, Davis M, Forgnes IC, Bassett US, Richardson PDI: Comparison of omeprazole and cimetidine in reflux oesophagitis: Symptomatic, endoscopic, and histological evaluations. Gut 31:968–972, 1990Google Scholar
  13. 13.
    Tijtgat GNJ, Nicolai JJ, Reman FC: Efficacy of different doses of cimetidine in the treatment of reflux oesophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 99:629–634, 1990Google Scholar
  14. 14.
    Johnsson F, Joelsson B, Gudmundsson K, Grieff L: Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 22:714–718, 1987Google Scholar
  15. 15.
    Sonnenberg A, Lepsien G, Müller-Lissner SA, Koelz HR, Siewert JR, Blum AL: When is esophagitis healed? Esophageal endoscopy, histology, and function before and after cimetidine treatment. Dig Dis Sci 27:297–302, 1982Google Scholar
  16. 16.
    Tijtgat GNJ: Endoscopy of the oesophagus.In Annual of Gastrointestinal Endoscopy. PB Cotton, GNJ Tijgat, CB Williams (eds). London, Current Science, 1989, pp 9–22Google Scholar
  17. 17.
    Savary M, Miller G: The Esophagus. Handbook and Atlas of Endoscopy. Solothurn, Gassman, 1978Google Scholar
  18. 18.
    Tijtgat GNJ: Medical therapy of reflux esophagitis.In Diseases of the Esophagus. JR Siewert, AH Hölscher (eds). Heidelberg, Springer-Verlag, 1988, pp 1137–1146Google Scholar
  19. 19.
    Klinkenberg-Knol, Jansen JNBJ, Festen HPM, Meuwissen SGM, Lamers CBHW: Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1:349–351, 1987Google Scholar
  20. 20.
    De Caestecker JS, Blackwell JN, Pryde A, Heading RC: Daytime gastro-oesophageal reflux is important in oesophagitis. Gut 28:519–526, 1987Google Scholar
  21. 21.
    Kruse-Andersen S, Wallin L, Madsen T: Reflux patterns and related oesophageal motoractivity in gastro-oesophageal reflux disease. Gut 31:633–638, 1990Google Scholar
  22. 22.
    De Meester TR, Wang CI, Wernly JA, Little AG, Pellegrini CA, Klementschitsch P, Bermudez G, Johnson LF, Skinner DB: Technique, indications and clinical use of 24 hour esophageal pH-monitoring. J Thorac Cardiovasc Surg 79:656–670, 1980Google Scholar
  23. 23.
    Jenkinson LR, Norris TL, Barlon AP, Watson A: Acid reflux and oesophagitis—day or night? Gullet 1:36–44, 1990Google Scholar
  24. 24.
    Pace F, Sangaletti O, Bianchi Porro G: Daytime reduction of gastro-oesophageal reflux after healing of oesophagitis and its value as an indicator of favourable response to maintenance treatment. Gut 31:1025–1029, 1990Google Scholar
  25. 25.
    Fiorucci S, Santucci L, Perrone E, Abbritti F, Morelli A: Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis. Scand J Gastroenterol 24:671–677, 1989Google Scholar
  26. 26.
    Orr WC, Robinson MC, Humphries TJ, Antonello J, Cagliola A: Dose response effects of famotidine on patterns of gastro-oesophageal reflux. Aliment Pharmacol Ther 2:229–235, 1988Google Scholar
  27. 27.
    Johansson KE, Tibbling L: Gastric secretion and reflux pattern in reflux oesophagitis before and during ranitidine treatment. Scand J Gastroenterol 21:487–492, 1987Google Scholar
  28. 28.
    Collen MJ, Lewis JH, Benjamin SB: Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 98:654–661, 1990Google Scholar
  29. 29.
    Sandmark S, Carlsson R, Fausa O, Lundell L: Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 23:625–632, 1988Google Scholar
  30. 30.
    Jansen JBMJ, Baak LC, Lamers CBHW: Effect of increasing doses of ranitidine on exposure of the oesophagus to gastric acid in patients with reflux oesophagitis. Scand J Gastroenterol 23(suppl 154):2–5, 1988Google Scholar
  31. 31.
    Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarlegio CA, Cornelius MJ, Gardner JD, Jensen RT: Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: Comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 88:1016–1033, 1985Google Scholar
  32. 32.
    McCallum RW, Chremos AN, Kuljian B, Tuyp-Visich MA, Huber PB: Mk-208, a novel histamine H2-receptor antagonist inhibitor with prolonged anti-secretory effects. Dig Dis Sci 30:1139–1144, 1985Google Scholar
  33. 33.
    Berenson M, Simon TJ, Berlin RG, Stein DT, Roufail WM, Kogut DG, Snapinn S, Cagliola AJ, Fong C: Bid regimens of an H2-receptor antagonist heal erosive esophagitis: Results of a US, double-blind, randomized, multi-center trial. Gastroenterology 97:372A, 1990Google Scholar
  34. 34.
    Edge DP: High dose famotidine in ranitidine resistant severe oesophagitis: A pilot study. NZ Med J 103:150–152, 1990Google Scholar
  35. 35.
    Simon TJ, Berlin RG, Lipping RW, Stauffer LA, Gilde LR: Results of an international double-blind, multicenter trial comparing BID dosages of H2-receptor antagonists: Relationship between pharmacodynamic effect on esophageal reflux and healing of erosive esophagitis. Am J Gastroenterol 85:42A, 1990Google Scholar
  36. 36.
    Wesdorp E, Bartelsman J, Pape K, Dekker W, Tijtgat GN: Oral cimetidine in reflux esophagitis: A double blind controlled trial. Gastroenterology 74:821–824, 1978Google Scholar
  37. 37.
    Mann SG: The place of famotidine in anti-ulcer therapy. Aliment Pharmacol Ther 1:504–509, 1987Google Scholar
  38. 38.
    Hernández-Muñoz R, Caballeria J, Baraona E, Uppal R, Greenstein R, Lieber ChS: Human gastric alcohol dehydrogenase: Its inhibition by H2-receptor antagonists, and its effects on the bioavailability of ethanol. Alcohol Clin Exp Res 6:946–950, 1990Google Scholar

Copyright information

© Plenum Publishing Corporation 1993

Authors and Affiliations

  • I. C. E. Wesdorp
    • 1
    • 2
    • 3
  • W. Dekker
    • 1
    • 2
    • 3
  • H. P. M. Festen
    • 1
    • 2
    • 3
  1. 1.Department of GastroenterologyAndreas ZiekenhuisAmsterdamThe Netherlands
  2. 2.Department of Internal MedicineElisabeth GasthuisHaarlemThe Netherlands
  3. 3.Grootziekengasthuis's-HertogenboschThe Netherlands

Personalised recommendations